SAN DIEGO--(BUSINESS WIRE)--Jan. 14, 2004--Molecular Imaging Corporation (“MLRI” or the “Company”) (OTC BB: MLRI) announced today that it has named Dennis Mulroy as its Chief Financial Officer. Mr. Mulroy has 16 years of experience as Vice President of Finance and Chief Financial Officer for companies in various industries. Mr. Mulroy’s background includes numerous activities requisite for the profitable growth of Molecular Imaging Corporation; his industry experience includes working with a Big 4 CPA Firm, Life Sciences, Medical Device, Telecommunications and Computer Technology companies.
Paul J. Crowe, President and CEO, commented: “We are delighted to have Dennis join our organization at this time. Dennis will strengthen our management team and with his broad experience provide the financial acumen required as Molecular Imaging Corporation continues to grow.”
Mr. Mulroy added, “I believe the Company is well positioned for further growth. I have been an integral member of management teams that have elevated companies to sustained profitability, and I believe this management team can be equally successful.”
About Molecular Imaging Corporation
Molecular Imaging Corporation (www.molecularimagingcorp.com) is a leading national provider of molecular imaging (MI) services to the healthcare industry. MI is a powerful information-based procedure used to diagnose, monitor and assess disease severity for many cancers, cardiovascular disease and neurological disorders. The Company operates mobile and permanent imaging sites for hospitals, medical centers and physician offices across the U.S. The Company’s clinical web site, www.PETadvances.com addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients.
Molecular Imaging (MI) is a medical imaging procedure that displays metabolic and functional characteristics of disease. Other conventional imaging procedures such as X-Ray, Computed Tomography (CT), Diagnostic Ultrasound and Magnetic Resonance Imaging (MRI) systems provide physicians with anatomical information. Because diseases like cancer, cardiac and neurological disorders often exhibit altered metabolism before the anatomy is changed, MI helps physicians effectively detect and stage these problems at their earliest stages. That information helps define and guide appropriate treatment options, which can eliminate redundant testing, hospitalization, or non-beneficial therapies.
Certain statements contained in this press release are “forward-looking statements” within the meaning of applicable federal securities laws, including, without limitation, anything relating or referring to future financial results and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The companies undertake no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
Contact:
Molecular Imaging Corporation, San Diego Sue Kirk, 619-226-6738 skirk@molecularimagingcorp.com or Media and Investor Relations: Terry McGovern, 415-924-9900 tmcgovern@crosslinkfinancial.com
Source: Molecular Imaging Corporation
